Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer
Treatment with the RXR agonist IRX4204 significantly delays tumor formation and increases CD8-positive T-cell infiltration in ER-negative murine breast cancer models. This suggests that immune modulation may be critical for rexinoid-based prevention of ER-negative mammary tumors and supports their use in future breast cancer prevention trials for high-risk individuals. See related Spotlight, p. 133.
Authors
- Amanda Lanier (ORCID: https://orcid.org/0000-0003-0791-6882)
- Alejandro Contreras (ORCID: https://orcid.org/0000-0001-6668-823X)
- Xiaoqian Liu
- Michelle I. Savage (ORCID: https://orcid.org/0000-0003-4927-9471)
- Vidyasagar Vuligonda (ORCID: https://orcid.org/0000-0002-9736-7866)
- Martin E. Sanders (ORCID: https://orcid.org/0000-0002-0007-0338)
- Cassandra L. Moyer (ORCID: https://orcid.org/0000-0002-3247-1865)
- Altaf Mohammed (ORCID: https://orcid.org/0000-0003-1058-6909)
- Jamal Hill (ORCID: https://orcid.org/0000-0002-7828-9647)
- Darian Coleman
- Shizuko Sei (ORCID: https://orcid.org/0000-0002-4822-6602)
- Powel H. Brown (ORCID: https://orcid.org/0000-0002-3398-163X)
- Abhijit Mazumdar (ORCID: https://orcid.org/0000-0002-8174-1251)
- Jitesh D. Kawedia (ORCID: https://orcid.org/0000-0001-9685-9378)
- Yanxia Ma (ORCID: https://orcid.org/0000-0003-3836-3889)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Opexa Therapeutics (United States) (US)
- National Cancer Institute (MY)
- United Therapeutics (United States) (US)
- National Cancer Institute (US)
- Io Therapeutics (United States) (US)
Publication Details
- Journal
- Cancer Prevention Research
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1158/1940-6207.capr-25-0081
- Primary Topic
- Retinoids in leukemia and cellular processes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Prevent Cancer Foundation
- University of Texas MD Anderson Cancer Center
- National Cancer Institute